Canntab Therapeutics Limited has provided an update on the recent product delivery of its unique pharmaceutical cannabinoid solutions to the Nova Scotia Liquor Corporation (NSLC).
The company said that on August 15, 2022, it completed its first shipment of 5mg and 10mg THC InstaCann tablets to the NSLC, totaling 300 bottles of each SKU. These products are now available on the NSLC's online platform and will be available in its brick-and-mortar stores starting today, August 22, 2022.
"This is a continuation of our efforts to expand our sphere of influence across not only Ontario, but the rest of the Canadian provinces," Richard Goldstein, the company's co-founder, CFO, and interim CEO said in a statement.
READ: Canntab Therapeutics names Richard Goldstein as interim CEO, replacing Larry Latowsky
Goldstein added: "While we have our online eCommerce store open for our medical patients, getting into more retail locations while also being listed with the NSLC's online platform is another positive move for Canntab. We are leaders in the oral delivery system of cannabis in the market today."
Canntab is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of cannabinoid tablet formulations in multiple doses and timed-release combinations.
Long referred to as Cannabis 3.0 by the company, Canntab's proprietary cannabinoid tablet formulations provide doctors, patients and consumers with medical-grade solutions which incorporate all the features one would expect from any prescription or over-the-counter medication sold in pharmacies around the world. These include once-a-day and extended-release formulations, both providing an accurate dose and improved shelf stability.
Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License and a Cannabis Research License.
Contact the author at jon.hopkins@proactiveinvestors.com